CAS No.: 872365-14-5
Appearance: White fine powder
Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2).[3
As of 2016, it is in Phase III clinical trials for the treatment of asthma. Setipiprant (INN) (developmental code names ACT-129,968, KYTH-105) is a drug originally developed by Actelionwhich acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.
Fevipiprant is the drug for the treatment of hair loss dwindled, perhaps due more to commercial potential and chemical stability reasons than efficacy as the later studies of Setipiprant have focused on different chemical forms of the drug and combining it with various nanoparticles to enhance delivery.
Tel: +86 29 8807 1646
Mobile: +86 181 9248 9506
Fax: +86 29 8807 1646
Add.: Rm2615 Block A Inland Port Mansion, Gangwu Avenue, Xi'an International Trade&Logistic Park, China.